Acceleration of Bone Repair in NOD/SCID Mice by Human Monoosteophils, Novel LL-37-Activated Monocytes

Zhifang Zhang, John E. Shively*
Department of Immunology, Beckman Research Institute of City of Hope, Duarte, California, United States of America

Abstract

**Background:** An incomplete understanding of bone forming cells during wound healing and ectopic calcification has led to a search for circulating cells that may fulfill this function. Previously, we showed that monoosteophils, a novel lineage of calcifying/bone-forming cells generated by treatment of monocytes with the natural peptide LL-37, are candidates. In this study, we have analyzed their gene expression profile and bone repair function.

**Methods and Findings:** Human monoosteophils can be distinguished from monocytes, macrophages and osteoclasts by their unique up-regulation of integrin α3 and down-regulation of CD14 and CD16. Monoosteophils express high mRNA and protein levels of SPP1 (osteopontin), GNMPB (osteoactivin), CHI3L1 (cartilage glycoprotein-39), CHIT1 (Chitinase 1), MMP-7, CCL22 and MAPK13 (p38MAPKδ). Monocytes from wild type, but not MAPK13 KO mice are also capable of monoosteophil differentiation, suggesting that MAPK13 regulates this process. When human monoosteophils were implanted in a freshly drilled hole in mid-diaphyseal femurs of NOD/SCID mice, significant bone repair required only 14 days compared to at least 24 days in control treated injuries.

**Conclusion:** Human derived monoosteophils, characterized as CD45+α3β1CD34-CD14- BAP (bone alkaline phosphatase)-, can function in an animal model of bone injury.

Citation: Zhang Z, Shively JE (2013) Acceleration of Bone Repair in NOD/SCID Mice by Human Monoosteophils, Novel LL-37-Activated Monocytes. PLoS ONE 8(7): e67649. doi:10.1371/journal.pone.0067649

Editor: Edward E. Schmidt, Montana State University, United States of America

Received February 21, 2013; Accepted May 20, 2013; Published July 3, 2013

Copyright: © 2013 Zhang, Shively. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: City of Hope funded. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jshively@coh.org

Introduction

Bone generation, maintenance and repair involve osteoblasts, osteoclasts, and osteocytes. Osteoblasts are cells of mesenchymal stem cell (MSC) origin that secrete bone-matrix proteins and promote mineralization. Differentiated osteoblasts embedded in the bone matrix or osteocytes have an as-yet unclear role in mechanotransduction [1]. Osteoclasts are cells of hematopoietic origin that decalcify and degrade the bone matrix by acid degradative and proteolytic degradation. They are large, multinucleated cells formed by the fusion of precursor cells of the monocyte–macrophage lineage. Osteoclasts may be generated in vitro by treatment of monocytes with RANKL and M-CSF [2,3].

An incomplete understanding of bone forming cells has led to an unfilled clinical need including healing of nonunion of bone fractures and prevention of ectopic calcification [4,5]. Since wound healing involves the recruitment of circulating immune cells to the injured site and bone marrow has a unique structural relationship with broken bone, immune cells have been proposed to play a role in bone repair [6]. Several CD34+ cell populations derived from peripheral blood with a hematopoietic lineage phenotype have been shown to have the potential to differentiate to osteoblast-like cells, such as endothelial progenitor cells (EPCs) [7], monocyte-derived mesenchymal progenitors (MOMPs) [8], circulating osteoblast-lineage cells (COCs) [9], fibrocytes [10], and circulating osteogenic precursor (COP) cells [11].

Two recent reports directly implicated purified peripheral blood monocytes as potential calcifying cells in ectopic bone formation [12] and vascular calcification [13]. First, Fadini et al. [13] showed that a subpopulation of monocytes (CD45+CD14+CD68+CD34−) that expressed surface osteocalcin and bone alkaline phosphatase (BAP), termed myeloid calcifying cells (MCC), formed spotty calcifications when implanted in Matrigel plugs in nude mice. Second, we demonstrated that monoosteophils (CD45+CD34+CD14+CD16−CD90−BAP-), derived from LL-37 treated human CD14+ monocytes, express some characteristic proteins of both osteoblasts and osteoclasts and are able to form bone in both in vitro and in vivo models [12]. Since LL-37 is produced by keratinocytes, granulocytes and macrophages during inflammation and recruits monocytes [14–16], it is possible that the recruited monoosteoblasts undergo LL-37 induced differentiation into monoosteophils, which in turn initiate bone repair.

Therefore, we investigated the gene expression profile and bone repair function of monoosteophils. Here, we show that monoosteophils can be distinguished from monocytes, macrophages and osteoclasts by their unique up-regulation of integrin α3. Monoosteophils express high mRNA and protein levels of SPP1 (osteopontin), GNMPB (osteoactivin), CHI3L1 (cartilage glycoprotein-39), CHIT1 (Chitinase 1), MMP-7, CCL22 and MAPK13 (p38MAPKδ). Monocytes from wild type but not MAPK13 KO
mice were able to differentiate into monoosteophils upon LL-37 treatment, suggesting that MAPK13 is a key signal molecule for the differentiation of monoosteophils. When human monoosteophils were implanted in a freshly drilled hole in mid-diaphyseal femurs of NOD/SCID mice, significant bone repair required only 14 days compared to at least 24 days in control treated injuries. Thus, human derived monoosteophils, characterized as CD45+α3β1+CD34−CD14−BAP− cells, can function in an animal model of bone injury.

Results

SEM/EDS Analysis of Monoosteophil-formed Nodules

We previously showed that monoosteophils built refractive, raised granules on the surface of osteologic discs that were identified as inorganic phosphate deposits by von Kossa staining [12]. In order to verify that the deposits were mineralized calcium phosphate, we used scanning electron microscopy (SEM) coupled with an energy dispersive X-ray spectroscopy (EDS) analyzer to investigate the elemental composition of the granules. As shown in Figure 1, the deposits contained phosphorus, calcium, carbon and sodium, demonstrating that monoosteophils produce deposits of typical calcifying/bone-forming cells.

Differentiation Markers and Proliferative Capacity of Monoosteophils

Monoosteophils become strongly adherent 6 days after a single treatment with 5 μM LL-37. Cell surface staining with a panel of anti-integrin antibodies (Figure S1) showed a unique expression of integrin α3 (CD49c) and the complex α3β1 compared to the lack of expression of integrin α3 on in vitro differentiated macrophages and osteoclasts (Figure 2A). Monoosteophils express high levels of integrin α6 (CD49e), while macrophages and osteoclasts express low levels (Figure S1). Ten percent of the cells were positive for integrin α3 at day 1, with a significant increase by day 3 after treatment with LL-37 (Figure S2). Integrin α3β1 is a cell surface receptor for collagen I, laminin, epiligrin, fibronectin, and entactin [17], all key ligands likely required for recruitment of these cells to a site of injury. Importantly, these cells were negative for surface scavenger receptor CD68 (Figure S3A), osteocalcin and BAP [12] distinguishing them from previously described COCs, MCCs, MOMPs, as well as osteoblasts and osteocytes.

The differentiation of LL-37 treated monocytes to monoosteophils takes place in two stages. Over the first 24 h there is a significant decrease in cell number, followed by an increase in cell number from day 2 to day 6, while the cell numbers of untreated monocytes continually decrease over the 6d period (data not shown). To determine the proliferative capacity of the monoosteophils, the cells were labeled with BrdU/7AAD or the Cell Proliferative Dye eFluor 670. Approximately 4% of the cells were BrdU positive vs 14% 7AAD positive at day 6, declining to <1% BrdU positive at day 21 (Figure 2B). Using cell proliferation dye eFluor 670, we found that monoosteophils synchronously divided at day 7 and day 14 with no preference for a subset of the cells (Figure 2C). Although control monocytes showed an accumulation of proliferation dye eFluor 670, microscopic examination revealed that a portion differentiated into macrophages and ingested the majority of apoptotic cells. Interestingly, when the monocytes were labeled with the classic proliferative dye CFSE, all of the cells died in both the untreated controls and LL-37 treated
monocytes (data not shown). Taken together, these results demonstrate that monoosteophils have a limited capacity for proliferation, and together with our previous study [12], show that they survive for extended periods, up to one year in culture.

Gene Expression Analysis of Monoosteophils

Since the monoosteophil is a novel type of calcifying/bone forming cell and shares some characteristics with osteoblasts that rely on bone morphogenic proteins (BMPs) for differentiation from their precursors, we analyzed their gene expression profile using a focused human BMP pathway array. In a comparison of day 6 monoosteophils with freshly isolated monocytes (day 0), the most dramatic up-regulated gene was MAPK13 (p38MAPKδ), while most other important BMP pathway genes, such as Smad1-5, BMP2, BMP4, FOS, ATF5, and p38MAPKα/β/γ were down-regulated or unchanged (Table S1). Since this analysis suggested that monoosteophils utilize a pathway distinct from the BMP pathway, the more comprehensive Affymetrix gene chip analysis was employed. In this analysis over 3,977 genes were found to be differentially expressed between the two groups (p<0.05), of which 2,146 genes were up-regulated and 1,831 genes were down-regulated. Genes unique to monoosteophils as well as found in osteoblasts, osteocytes or osteoclasts are summarized in Table S2. The 50 top scoring up-regulated and down-regulated genes are shown in Figure 3. Not surprisingly, the top 2 up-regulated genes are bone formation related genes, SPP1 (2,694 fold) or osteopontin and GPNMB (2,477 fold) or osteoactivin. Osteopontin, initially described as a major noncollagenous protein in bone [also called bone sialoprotein I], is known to be involved in bone remodeling, wound repair, immune function, angiogenesis, and cell survival.

Figure 2. Differentiation markers and proliferative capacity of monoosteophils. A. Monocytes were incubated in the absence or presence of LL-37 (5 μM), GM-CSF (20 ng/mL), M-CSF (50 ng/mL), or M-CSF and RANKL (both at 25 ng/mL) for 6 days. Surface staining of Integrin α3 and α3β1 were analyzed using flow cytometry. B–C. Monocytes were incubated in the presence of 5 μM LL-37 for different days and proliferative capacity was detected using either (B) FITC BrdU/7AAD flow kit or (C) Cell proliferation dye eFluor 670. Data shown were from three independent experiments. doi:10.1371/journal.pone.0067649.g002
monocyte recruitment, just as LL-37 is also a chemotactic factor In this respect, the up-regulation of (CRAMP in mouse, LL-37 in human) promote atherosclerosis by role [27]. Furthermore, it was recently reported that cathelicidins (atherosclerosis related genes in which activated monocytes play a role [27]. Furthermore, it was recently reported that cathelicidins (CRAMP in mouse, LL-37 in human) promote atherosclerosis by enhancement of the recruitment of inflammatory monocytes [20]. In this respect, the up-regulation of CCL22 (macrophage-derived chemokine, 452 fold) by monoosteophils may be responsible for monocyte recruitment, just as LL-37 is also a chemotactic factor for monocytes. Another up-regulated gene of interest is CHI3L1 (743 fold, chitinase 1), elevated in Gaucher disease, atherosclerosis and tuberculosis, suggesting unanticipated roles in bone repair. In accordance with the BMP pathway array results, the top signal pathway gene was MAPK13 (106 fold, Table S2). In terms of top down-regulated genes, VCAN (-2,104 fold, versican) stands out for its normal expression in chondrocytes [29]. The lack of its expression, suggests that monoosteophils do not express chondroitin sulfate, suggesting a negative role for this proteoglycan in bone repair. Taken together, these analyses not only distinguish monoosteophils from classic bone remodeling cells, but reveal connections to new pathways of bone repair and pathological conditions such as atherosclerosis that can involve calcification of tissues.

Monoosteophils Secrete High Amounts of Osteopontin, Osteoactivin, Cartilage Glycoprotein-39, Chitinase 1, MMP-7 and CCL22

To confirm gene expression result at the protein level, we quantified the concentration of osteopontin, osteoactivin, cartilage glycoprotein-39, chitinase 1, MMP-7, and CCL22 in cultured supernatants of monocytes treated in a variety of ways at day 1, 3, and 6. As shown in Figure 4, all analyzed proteins of LL-37 treated monocytes (monoosteophils) are significant higher than untreated controls at day 6, and levels of osteoactivin, cartilage glycoprotein-39, chitinase 1, and MMP-7 were uniquely elevated in comparison with GM-CSF treated, GM-CSF+IL-4 treated (DCs) or M-CSF+RANKL treated (osteoclasts) monocytes at both day 3 and day 6. At day 1, osteoactivin and MMP-7 were highest in monoosteophils compared to the other monocyte-differentiated cell types. CCL22, the top chemokine hit in the gene chip analysis (Figure 3), significantly increased at day 6, but was low at day 1 and 3; however, this chemokine is not unique to monoosteophils, with expression also seen in GM-Mac and M-Mac (Figure 4). The receptor for CCL22, CCR4, was low at day 6 compared to GM-Mac and M-Mac (Figure S3B), suggesting that expression of its self ligand CCL22 was responsible.

MAPK13 Signaling Pathway Plays Key Role in the Differentiation of Monoosteophils

Osteoblasts and osteoclasts, among the most studied resident bone cells, critically rely on signaling pathways involving ERK, p38MAPKζ/β/γ and Smads [30,31]. Phospho-p38MAPKζ/β/γ, phospho-ERK42/44, RunX2 and osterix were either low or unchanged in LL-37 treated monocytes at day 6 compared to untreated controls (Figure S4A–D). Time course analysis of phospho-Smad1/5/8 is especially interesting in that freshly isolated monocytes (0 d) are highly activated in this regard and lose this marker as soon as 1 d in both untreated and LL-37 treated cells (Figure 5A). In the case of monoosteophils, there is a slow increase over time for phospho-Smad1/5/8, suggesting a potential role for this signaling pathway. In accordance with our gene chip analysis, MAPK13 was dramatically up-regulated from 0–6 d during monoosteophil differentiation (Figure 5B). A time course of the expression of MAPK13 and 6 other genes potentially associated with MAPK13 showed that two of the genes (CHI3L1 and Chitinase 1) followed the same kinetics as MAPK13, suggesting that their expression profiles were related (Figure S5). Due to lack of reagents, we were unable to measure the degree of activation of MAPK13, but given its unique up-regulation, it is likely activated. Given the potential role of MAPK13 in human monoosteophil differentiation, we directly assessed its role in the differentiation of mouse monocytes into monoosteophils. Treatment of murine monocytes from wild type but not MAPK13 KO mice with CRAMP (murine LL-37) was able to differentiate these cells with an identical morphology and survival characteristics to authentic human monoosteophils (Figure 5C). Analysis of the cell surface markers of CRAMP vs GM-CSF treated murine monocytes for α2 integrin, 36 integrin, CD68 and alkaline phosphatase revealed up-regulation of both α2 and 36 integrins, characteristics shared with LL-37 treated human monocytes (Figure S6).

In other studies, MAPK13 is up-regulated in arterial smooth muscle cells undergoing calcification [32], a process likely involving monocytes in an inflammatory milieu. MAPK13 null mice exhibit improved glucose tolerance due to enhanced insulin secretion from pancreatic β cells and are protected against high-fat-feeding-induced insulin resistance and oxidative stress-mediated β cell failure [33]. Thus, MAPK13 may play multiple roles in signal transduction, depending on its tissue expression.

Monoosteophils Accelerate Cortical Bone Repair in a Drilled Hole Bone Defect Model

In order to examine the bone repair capability of monoosteophils in vivo, drilled hole defects in NOD/SCID mouse femurs were used as a model [34]. Since treatment of monocytes with LL-37 for 24 hours is sufficient to trigger monoosteophil differentiation in vitro (Figure S7), both 1 d and 6 d LL-37 generated monoosteophils in Matrigel were applied to drilled hole defects. After application of these cells for 14 days, mouse femurs were analyzed by low-resolution µCT. In Matrigel only (no cells) or Matrigel-monocyte control groups the cortical defect along with bone callus formation was still present at day 14. On the other hand, cortical defects in either the 1 d or 6 d monoosteophil generated groups were almost completely repaired with only trace evidence of bone callus formation (Figure 6A–B). These results indicate that 1 d and 6 d LL-37 treated monocytes have the same capacity to accelerate bone repair. Advantages of using the 1 d generated cells include less time of pretreatment and easier cell harvesting since the 1 d cells are loosely adherent compared to strongly adherent 6 d cells.
The kinetics of the bone repair progress was performed using μCT (Fig. 6C–E). In the control monocyte group, the critical bone defect was not completely repaired even after twenty-four days. Bone callus formation was obvious at day 4, reached a maximum at day 8, and almost disappeared at day 24. In the LL-37 treated monocyte group, the bone defect was significantly repaired at day 14, similar to the degree of repair as day 24 in the control group, and completely repaired at day 24. Notably, there is no clear bone callus formation during the entire process of bone regeneration in the monoosteophil group.

**Discussion**

Bone has a substantial capacity for repair and regeneration in response to injury. Both processes involve a complex integration of cells, growth factors, and extracellular matrix. Although osteoblasts, osteocytes and osteoclasts are resident bone cells, an increasing amount of evidence points to the potential of bone marrow derived hematopoietic cells to engraft into damaged bone and participate in the calcification processes.

Examples of calcifying/bone forming cells from hematopoietic cell lineage are as EPCs [7], MOMPs [8], COCs [9], fibrocytes [10], COP cells [11], monoosteophils [12] and MCCs [13]. They can be grouped into three categories based on their cell surface markers and in vitro generation procedures. The first group are CD34<sup>+</sup> progenitor cells, COCs [9,35] and EPCs [36–38] have the capacity to differentiate to osteoblastic-like cells [7,37]. The second group are CD34<sup>+</sup>CD45<sup>+</sup>CD14<sup>+</sup> peripheral blood cells, including fibrocytes [10,39], MOMPs [8], and COP [11], isolated from cultured PBMCs and, like MSCs, are able to differentiate into osteoblastic, adipocytic, and myocytic cells. Since CD34 is a marker of hematopoietic stem cells, these cells may be able to differentiate into MSCs, a process called transdifferentiation, followed by differentiation into osteoblast-like cells, adipocytes and chondrocytes. The third group are derived from circulating CD34<sup>+</sup>CD45<sup>+</sup>CD14<sup>+</sup> cells, or monocytes, and include monoosteophils [12] and MCCs [13], both of which have the capacity to differentiate into novel calcifying/bone forming cells. CD14, a unique lineage marker for human monocytes, is lost on monoosteophils and retained on MCCs. The fact that monocytes may differentiate into a wide range of cellular phenotypes is well known and fits with their role in wound repair [40].

Since monoosteophils are derived from peripheral blood CD34<sup>+</sup>CD45<sup>+</sup>CD14<sup>+</sup> monocytes and highly express integrin α3, but down-regulate CD14 [12], monoosteophils can be cell surface phenotyped as CD45<sup>+</sup>α3β1<sup>+</sup>CD34<sup>+</sup>CD14<sup>+</sup>BAP<sup>+</sup> cells. Integrin α3β1 is involved in osteoblast-like cell differentiation [41] and is associated with skeletal metastasis of breast and prostate cancer [42,43], and thus, its up-regulation in monoosteophils may target them to the bone. Furthermore, monoosteophils express different surface markers from MCCs, fibrocytes and MOMPs, suggesting that each may play different roles in remodeling bone.

Given the fact that implantation of monoosteophils in the drilled bone model accelerated bone repair, it is likely that monoosteophils are responsible for at least initiation of the bone repair. Moreover, monoosteophils are also capable of phagocytosis and anti-inflammation (releasing predominant anti-inflammatory cytokines) [12], leading us to hypothesize that monoosteophil treatment may shorten the reactive phase and reparative phase of bone repair, thereby accelerating the bone repair process, as evidenced by lack of callus formation in our study.

Monoosteophil express and release significantly high levels of osteopontin, osteoactivin, cartilage glycoprotein-39, chitinase 1, MMP-9 and -7, CCL-22 and MAPK13. Osteoactivin, cartilage

---

**Figure 3. Microarray analysis of monoosteophils.** Gene expression profiles of 6 day monoosteophils in comparison with freshly isolated monocytes were performed using Affymetrix gene chip analysis: top 50 up-regulated (A) and down-regulated (B) were shown as fold change. doi:10.1371/journal.pone.0067649.g003
Figure 4. Monoosteophils release high level of osteopontin, osteoactivin, cartilage glycoprotein-39, chitinase 1, MMP-7 and CCL22. Monocytes were incubated in the absence or presence of LL-37 (5 μM), GM-CSF (20 ng/mL), GM-CSF+IL-4 (both 20 ng/mL), M-CSF (50 ng/mL) or M-
glycoprotein-39, chitinase 1, and MMP-7 distinguish monoosteophils from control monocytes, macrophages, DCs, and osteoclasts. The fact that monocytes from wild type but not MAPK13 KO mice were able to differentiate into monoosteophils after LL-37 treatment confirms a critical role for this kinase in monoosteophil differentiation. An important question that remains is which receptor(s) are responsible for the activation of the monoosteophil resulting in the downstream activation of MAPK13, and to a lesser extent Smad1/5/8. Future studies will be directed at the possible connection of MAPK13 signaling.

In a recent review, monoosteophils were hypothesized to be involved in the process of bone maintenance [7], however our present study suggests that their primary role may be in bone repair during wounding, in keeping with the anti-inflammation function of LL-37 which is released during tissue injury. Thus, monoosteophils may potentially be useful in gene and cell therapy protocols to enhance bone formation, remodeling, or regenera-

**Figure 5. pSmad1/5/8 and MAPK13 signaling in the differentiation of monoosteophils.** Human monocytes were incubated in the absence or presence of LL-37 (5 μM). Cells were harvested on days 0–6 and pSmad1/5/8 (A) and MAPK13 (B) were analyzed by western blot. (C) Mouse monocytes were isolated from bone marrow of MAPK13 KO or wild type mice, cultured at the concentration of 1 x 10^6 cells/mL in absence or presence of 5 μM CRAMP (murine LL-37) for 6 days, and observed using phase contrast microscopy (magnification, 200×). Data shown are representative of three independent experiments.

doi:10.1371/journal.pone.0067649.g005
tion, and in exploring the pathogenesis of ectopic calcification and musculoskeletal diseases, such as atherosclerosis, granuloma calcification and arthritis.

**Methods**

**Reagents**

LL-37 was synthesized by standard FMOC chemistry, purified by reversed phase HPLC, and the mass verified by nanospray mass spectrometry. EasySep® Human Monocyte Enrichment Kit were purchased from StemCell Technologies Inc (Vancouver, Canada), recombinant human GM-CSF, M-CSF, IL-4, and RANKL from ProSpec Tany TechnoGene Ltd (Rehovot, Israel), anti-RUNX2 (Clone 27-K) and anti-Osterix (Clone M-15) from Santa Cruz Biotechnology (Santa Cruz, USA), anti-integrin α3/β1 (Clone 2Q993) from US Biological (Swampscott, USA), PE anti-human CD29 (Integrin β1, clone: MAR4), PE anti-human CD18 (Integrin β2, clone 6.7), BioCoat™ Osteologic™ Disc and FITC BrdU/7AAD Flow Kit from BD Biosciences (San Jose, USA). Anti-human integrin β3 (Clone: 2E5E11), anti-human integrin β4 (Clone: 3E1) and anti-human integrin β5 (Cat#: AB1926-20) were from EHD Millipore (Billerica, MA, USA), PE anti-human CD49d (Integrin α4, clone: 9F10), APC anti-human CD49e (Integrin α5, clone: NK-SAM-1), APC anti-human CD49f (Integrin α6, clone: GoH3), FITC anti-human CD68 (CloneY1/82A) and Alexa Fluor 647 anti-CCR4 (Clone TG6/CCR4) from Biolegend (San Diego, USA), TaqMan array human Pathway Plate from Invitrogen Corp (Grand Island, USA), cell proliferation Dye eFluor670 and eBioscience Fixation/Permeabilization Concentrate and Diluent from eBioscience (San Diego, USA), MMP-7 ELISA Kit from RayBiotech, Inc (Norcross, USA), anti-human p38MAPKα/β/γ (Rabbit), anti-phospho-ERK1/2 (Rabbit), anti-phospho-Smad1/5/8 (Rabbit) and anti-MAPK13 (p38MAPKδ) (Rabbit) from Cell Signaling Technology (Danvers, USA), and ELA kits of Osteopontin, GPNMB/osteoactivin, Cartilage glycoprotein-39 (also called Chitinase 3-like 1), Chitinase 1, MMP-7, and CCL22 from R&D systems (Minneapolis, USA).

**Monocyte Isolation and Differentiation**

The use of anonymous discard blood samples without the requirement for informed consents was approved by the City of Hope IRB (IRB # 99132). Peripheral blood mononuclear cells (PBMCs) were isolated from citrated human blood (discard blood from anonymous donors) by centrifugation over Ficoll-Paque Plus (GE healthcare biosciences, Pittsburgh, PA, USA) density gradient. Monocytes were separated using EasySep® Human Monocyte Enrichment Kit from PBMCs. The purified monocytes were stained with anti-CD14-FITC and analyzed using flow cytometry on a FACSCanto II. Monocytes with ≥95% purity were suspended at 1×10⁶ cells/mL in RPMI 1640 medium supplemented with 10% FBS and treated with 5 μM LL-37 for monoosteophil differentiation. For macrophage differentiation, monocytes were treated with medium only, or 20 ng/mL GM-CSF, or 50 ng/mL M-CSF for 6 days. Monocyte-derived DCs were generated with GM-CSF and IL-4 (both at 20 ng/mL). Osteoclasts were differentiated from monocytes in the presence of RANKL and M-CSF (both at 25 ng/mL).

Figure 6. Monoosteophils accelerate cortical bone repair in the drilled-hole bone defect model. NOD/SCID mice were anesthetized with isoflurane, and holes (0.9 mm) were created in the mid-diaphysis of femur. **A–B.** Holes were filled with Matrigel (Ctrl), Matrigel +6 d Monoosteophils (6 d MOP, 3×10⁶ cells), Matrigel +1 d Monoosteophils (1 d MOP, 3×10⁶ cells), or Matrigel +1 d Monocytes (1 d Mo, 3×10⁶ cells). After 14 days, femurs were harvested and observed by visual analysis (A) and low resolution μCT (B). **C–D.** Holes were filled with Matrigel +1 d Monoosteophils (1 d MOP, 3×10⁶ cells) or Matrigel +1 d Monocytes (1 d Mo, 3×10⁶ cells). Bone repair was monitored by serial μCT using coronal (C) and transverse plane imaging (D) and quantitated as remaining defect area (mm²) (E) at days shown in the figure. doi:10.1371/journal.pone.0067649.g006
Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray Spectroscopy (EDS) Analysis

Monocytes at the cell concentration of 1×10⁶ cells/mL in RPMI1640 medium with 10% FBS were incubated with 5 μM LL-37 on BioCoat™ Osteologic™ Discs for 7 weeks in 5% CO₂ atmosphere and fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer for SEM. A Thermo Scientific NORAAN System 7 EDS (Thermo Fisher Scientific, Madison, WI, USA) incorporated into a SEM system was used for identification of the elemental composition of monocyte-osteophil-formded nodules on Osteologic Discs. Quantitative element maps of built-up structures were determined at high magnification.

Flow Cytometry

For cell surface staining, cells were washed with PBS, blocked with 10% human serum in PBS, stained with isototype controls or antibodies, washed 3 times with 1% BSA in PBS, and analyzed using FACSCanto II and FlowJo software. For intracellular staining, cells were washed with PBS, fixed and permeabilized with eBioscience Fixation/Permeabilization Concentrate and Diluent, and stained with primary isotype controls or antibodies. After washing with PBS containing 1% BSA and 0.1% saponin, cells were stained with secondary Alexa 488 conjugated antibodies. BrdU/7AAD and Cell proliferation Dye eFluor670 staining were performed according to manufacturer’s procedure.

Western Blot Analysis

Whole cell extracts of control or LL-37 treated monocyte were prepared using RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.5% deoxycholate and 0.1% SDS) containing protease inhibitor cocktail (Roche, Basel, Switzerland). Western blotting was performed with anti-human p38MAPKβ/γ (Rabbit), anti-phospho-ERk1/2 (Rabbit), anti-phospho-Smad1/5/8 (Rabbit), and anti-MAPK13 (p38MAPKβ) (Rabbit).

Gene Expression Profiling

mRNA was isolated from fresh monocytes (day 0) or 6 day LL-37-differentiated monosteophils with TRI reagents (Molecular Research Center, Cincinnati, OH). TagMan Human BMP Pathway Array analysis was performed according to the manufacturer’s company protocol (Invitrogen). Gene expression profiling of Affymetrix Human Genome Array was performed at the City of Hope Microarray Core and microarray data were analyzed using the software Gene Set Enrichment Analysis.

Enzyme Immunoassay (EIA)

Monocytes were incubated in the absence or presence of LL-37 (5 μM), GM-CSF (20 ng/mL), GM-CSF+IL-4 (both at 20 ng/mL), M-CSF (50 ng/mL) or M-CSF+RANKL (both at 25 ng/mL) for 1 day, 3 day or 6 day. Quantification of soluble Osteopontin, Osteoactivin/GPNMB, cartilage glycoprotein 39, Chitinase 1, MMP-7, and CCL22 was performed using commercially available EIA kits (R&D systems, Minneapolis, MN).

Immunofluorescence Staining

Monocytes were incubated in the presence or absence of 5 μM LL-37 for 6 days, washed twice with cold PBS, fixed and permeabilized with eBioscience Fixation/Permeabilization reagent. Unspecific binding was blocked with 10% human serum before staining with a monoclonal anti-RunX2 or anti-Osterix antibody at 4°C overnight. Cells were incubated with a secondary Alexa Fluor 488 labeled donkey anti-mouse-Ig antibody (Invitro-
mL) for 6 days. Surface staining of integrin α1-6 and β1-5 were analyzed using flow cytometry. Data shown were from at least three independent experiments.

(Fig. S2) Time course of expression of integrin α3 and α3β1 during monoosteophil differentiation. Monocytes were incubated in the presence of LL-37 (5 μM), GM-CSF (20 ng/mL) or M-CSF (50 ng/mL) for 1 or 3 days. Surface staining of integrin α3 and α3β1 were analyzed using flow cytometry. Data shown were from at least three independent experiments.

(Fig. S3) CD68 and CCR4 expression in monoosteophils and macrophages. Monocytes were incubated in the absence or presence of LL-37 (5 μM), GM-CSF (20 ng/mL) or M-CSF (50 ng/mL) for 6 days. Surface staining of CD68 and CCR4 were analyzed using flow cytometry. Data shown were from at least three independent experiments.

(Fig. S4) p38MAPKα/β/γ, ERK, RunX2 and Osterix signaling in monoosteophils. Monocytes were incubated in the absence or presence of LL-37 (5 μM). Cells were harvested on day 6 and p38MAPKα/β/γ, pERK42/44, RunX2 and osterix were analyzed using western blot or fluorescence microscopy. Data shown were from three independent experiments.

(Fig. S5) mRNA levels of targeted genes during monoosteophil differentiation. Monocytes were treated with 5 μM LL-37 and harvested at different time points. Gene expression of treated cells in comparison with fresh monocytes was performed using gene chip analysis. Targeted genes were shown as fold change.

(Fig. S6) Integrin α3 and α6, CD68, and alkaline phosphatase expression on the surface of 6 d monoosteophils from wild type mice. Negatively isolated mono- cytes from bone marrow cells of wild type mice were incubated in the presence of CRAMP (mouse LL-37, 5 μM) or mouse GM-CSF (20 ng/mL) for 6 days. Surface staining of integrin α3 and α6, CD68 and alkaline phosphatase were analyzed using flow cytometry. Data shown were from three independent experiments.

References
1. Seeman E, Delmas PD (2006) Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 354: 2250–2261.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.
3. Quinn JM, Elliott J, Gillespie MF, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139: 4424–4427.
4. Khan AN, Al-Jahdali HJ, Allen CM, Irlon KL, Al Ghamem S, et al. (2010) The calcified lung nodule: What does it mean? Ann Thorac Med 5: 67–79.
5. Sage AP, Tintut Y, Demer LL (2010) Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 7: 528–536.
6. Pignolo RJ, Kassem M (2011) Circulating osteogenic cells: implications for injury, repair, and regeneration. J Bone Miner Res 26: 1685–1693.
7. Fadini GP, Alberico M, Menegazzi L, Boscaro E, Vigli de Kreutzenberg S, et al. (2011) Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res 108: 1112–1121.
8. Lehrer RI, Ganz T (2002) Cathelicids: a family of endogenous antimicrobial peptides. Curr Opin Hematol 9: 18–22.
9. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPR1) as a receptor to chemotactact human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069–1074.
10. Nobel PH, Burdick MD, Stierer RM (2010) Human circulating fibrocytes have the capacity to differentiate osteoblast and chondrocytes. Int J Biochem Cell Biol 42: 662–671.
11. Suda RK, Billings PC, Egon KP, Kim JW, McCarrick-Walmsley R, et al. (2009) Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells 27: 2009–2019.
12. Zhang Z, Shively JE (2010) Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL-37 treated monocytes. PLoS One 5: e13985.
13. Conceived and designed the experiments: ZZ JES. Performed the experiments: ZZ. Analyzed the data: ZZ. Wrote the paper: ZZ JES.
18. Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179–184.
19. Safadi FF, Xu J, Smock SL, Rico MC, Owen TA, et al. (2001) Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem 84: 12–26.
20. Abdelmagid SM, Barfe MP, Arango-Huisjara I, Owen TA, Popoff SN, et al. (2007) Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function. J Cell Physiol 210: 26–37.
21. Bateman JP, Safadi FF, Susin C, Wikesjo UM (2012) Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model. J Periodontal Res 47: 243–247.
22. Recklies AD, Ling H, White C, Bernier SM (2005) Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 280: 41213–41221.
23. Nyirkos P, Golds EE (1990) Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 269: 265–268.
24. Krause SW, Enell M, Kreutz M, Schwarzfischer L, Paulauskis JD, et al. (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 60: 540–545.
25. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, et al. (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 38: 618–626.
26. Kramer SM, Inada M (2008) Matrix metalloproteinases and bone. Bone 43: 7–18.
27. Laguna JC, Alegret M (2012) Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages. Pharmacogenomics 13: 477–495.
28. Doring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, et al. (2012) Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res 110: 1052–1056.
29. Benjamin M, Ralphs JR (2004) Biology of fibrocartilage cells. Int Rev Cytol 233: 1–45.
30. Zuo C, Huang Y, Bajs R, Sahal M, Li YP, et al. (2012) Osteoblastogenesis regulation signaling in bone remodeling. Osteoporos Int 23: 1653–1663.
31. Kataoka T, Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8: 147–159.
32. Shahbouh V, Shatzen EM, Ward SC, Young JJ, Bordheimser M, et al. (2010) Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcium or paracalcitol. J Cell Biochem 111: 911–921.
33. Sumara G, Formentini I, Collins S, Sumara I, Windak R, et al. (2009) Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell 136: 225–238.
34. Monfoleti L, Rahier B, Chassande O, Fricain JC (2010) Drilled hole defects in mouse femur as models of intramembranous cortical and cancellous bone regeneration. Calcif Tissue Int 86: 72–81.
35. Ejphali-Fatourechi GZ, Modder UI, Charrat-Charoenwityha N, Sanyal A, Undale AH, et al. (2007) Characterization of circulating osteoblast lineage cells in humans. Bone 40: 1370–1377.
36. Goss M, Modder UI, Gulati R, Rihal CS, Prasad A, et al. (2010) Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J 31: 2909–2914.
37. Matsumoto T, Kawamoto A, Kuroda R, Ishikawa M, Mifune Y, et al. (2006) Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. Am J Pathol 169: 1440–1457.
38. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221–228.
39. Bucala R, Spiegel LA, Chesney J, Hogen M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71–81.
40. Seta N, Kowama M (2007) Human circulating monocytes as multipotential progenitors. Keio J Med 56: 41–47.
41. Gronthos S, Simmons PJ, Graves SE, Robey PG (2001) Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 28: 174–181.
42. Lundstrom A, Holmblom J, Lindqvist C, Nordstrom T (1998) The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun 250: 735–740.
43. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T (1992) A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 52: 5395–5399.
44. Sahoo G, Arthur JS, Kuma Y, Peggie M, Harr J, et al. (2005) p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GSKAP. Embo J 24: 1134–1145.
45. Schindler EM, Huhes A, Gribben EL, Burns CJ, Yin Y, et al. (2009) p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69: 4648–4655.